A phase I clinical trial of avelumab in combination with decitabine as first line treatment of unfit patients with acute myeloid leukemia

Hong Zheng; Shin Mineishi; David Claxton; Junjia Zhu; Chenchen Zhao; Bei Jia; W. Christopher Ehmann; Witold B. Rybka; Seema Naik; Natthapol Songdej; Joseph J. Drabick; Raymond J. Hohl

doi:10.1002/ajh.26043

A phase I clinical trial of avelumab in combination with decitabine as first line treatment of unfit patients with acute myeloid leukemia

Hong Zheng, Shin Mineishi, David Claxton, Junjia Zhu, Chenchen Zhao, Bei Jia, W. Christopher Ehmann, Witold B. Rybka, Seema Naik, Natthapol Songdej, Joseph J. Drabick, Raymond J. Hohl

Research output: Contribution to journal › Letter › peer-review

22 Scopus citations

Original language	English (US)
Pages (from-to)	E46-E50
Journal	American Journal of Hematology
Volume	96
Issue number	2
DOIs	https://doi.org/10.1002/ajh.26043
State	Published - Feb 1 2021

All Science Journal Classification (ASJC) codes

Hematology

Access to Document

10.1002/ajh.26043

Cite this

Zheng, H., Mineishi, S., Claxton, D., Zhu, J., Zhao, C., Jia, B., Ehmann, W. C., Rybka, W. B., Naik, S., Songdej, N., Drabick, J. J., & Hohl, R. J. (2021). A phase I clinical trial of avelumab in combination with decitabine as first line treatment of unfit patients with acute myeloid leukemia. American Journal of Hematology, 96(2), E46-E50. https://doi.org/10.1002/ajh.26043

@article{8bac53e810ee4d9897eb9c19c58f0539,

title = "A phase I clinical trial of avelumab in combination with decitabine as first line treatment of unfit patients with acute myeloid leukemia",

author = "Hong Zheng and Shin Mineishi and David Claxton and Junjia Zhu and Chenchen Zhao and Bei Jia and Ehmann, {W. Christopher} and Rybka, {Witold B.} and Seema Naik and Natthapol Songdej and Drabick, {Joseph J.} and Hohl, {Raymond J.}",

note = "Funding Information: This work was supported in part by Penn State Cancer Institute (PSCI) Funds, the Penn State University Enhancing Health Initiative, the Kiesendahl Endowment funding, and an anonymous donation to PSCI for Cancer Research. The clinical trial was funded by Pfizer, as part of an alliance between Pfizer and Merck KGaA, Darmstadt, Germany. ",

year = "2021",

month = feb,

day = "1",

doi = "10.1002/ajh.26043",

language = "English (US)",

volume = "96",

pages = "E46--E50",

journal = "American Journal of Hematology",

issn = "0361-8609",

publisher = "John Wiley and Sons Inc.",

number = "2",

}

TY - JOUR

T1 - A phase I clinical trial of avelumab in combination with decitabine as first line treatment of unfit patients with acute myeloid leukemia

AU - Zheng, Hong

AU - Mineishi, Shin

AU - Claxton, David

AU - Zhu, Junjia

AU - Zhao, Chenchen

AU - Jia, Bei

AU - Ehmann, W. Christopher

AU - Rybka, Witold B.

AU - Naik, Seema

AU - Songdej, Natthapol

AU - Drabick, Joseph J.

AU - Hohl, Raymond J.

N1 - Funding Information: This work was supported in part by Penn State Cancer Institute (PSCI) Funds, the Penn State University Enhancing Health Initiative, the Kiesendahl Endowment funding, and an anonymous donation to PSCI for Cancer Research. The clinical trial was funded by Pfizer, as part of an alliance between Pfizer and Merck KGaA, Darmstadt, Germany.

PY - 2021/2/1

Y1 - 2021/2/1

UR - http://www.scopus.com/inward/record.url?scp=85096656582&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85096656582&partnerID=8YFLogxK

U2 - 10.1002/ajh.26043

DO - 10.1002/ajh.26043

M3 - Letter

C2 - 33146922

AN - SCOPUS:85096656582

SN - 0361-8609

VL - 96

SP - E46-E50

JO - American Journal of Hematology

JF - American Journal of Hematology

IS - 2

ER -

A phase I clinical trial of avelumab in combination with decitabine as first line treatment of unfit patients with acute myeloid leukemia

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Cite this